Rituximab therapy for refractory immune thrombocytopenic purpura in elder patients

Int J Hematol. 2010 Mar;91(2):336-7. doi: 10.1007/s12185-009-0486-z.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Humans
  • Immunologic Factors / administration & dosage*
  • Male
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab